The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
efficacy, and safety study of ciclesonide MDI for the treatment of symptomatic COVID-19
infection. Enrolled patients were male and female adults and adolescents 12 years of age or
older with confirmed COVID-19 infection who were currently exhibiting symptoms of the disease
and who were not currently hospitalized or under immediate consideration for hospitalization
at the time of enrollment. The study consisted of an initial
screening/enrollment/randomization visit, a 30-day treatment period, and a follow-up period.
Drug: Ciclesonide
160mcg Inhaler
Other Name: Alvesco
Drug: Placebo
Matching Placebo Inhaler
Inclusion Criteria
Patients eligible for enrollment in the study must meet all the following criteria:
1. Male and female adults and adolescents (12 years of age and above).
2. Positive SARS-CoV-2 rapid molecular diagnostic test within 72 hours prior to
enrollment.
3. Patient is not currently hospitalized or under immediate consideration for
hospitalization at the time of enrollment.
4. Patient is currently experiencing symptoms of fever, cough, and/or dyspnea.
5. Patient has an oxygen saturation level greater than 93%.
6. Ability to show adequate use of MDI, including inhalation technique.
7. Patient, parent/legal guardian, or legally-authorized representative must have signed
a written informed consent before administration of any study-specific procedures.
Exclusion Criteria
Patients meeting any of the following criteria are not eligible for participation in the
study:
1. Existence of any life-threatening co-morbidity or any other medical condition which,
in the opinion of the investigator, makes the patient unsuitable for inclusion.
2. History of hypersensitivity to ciclesonide.
3. Treatment with inhaled or intranasal corticosteroids within 14 days of the screening/
enrollment/randomization visit.
4. Treatment with oral corticosteroids within 90 days of the
screening/enrollment/randomization visit.
5. Participation in any other clinical trial or use of any investigational agent within
30 days of the screening/enrollment/randomization visit.
6. Currently receiving treatment with hydroxychloroquine/chloroquine.
7. Patients with cystic fibrosis.
8. Patients with idiopathic pulmonary fibrosis.
University of Buffalo
Buffalo, New York, United States